Tumor‐infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
Abstract
Prostate cancer is characterized by T‐cell exclusion, which is consistent with their poor responses to immunotherapy. In addition, T‐cells restricted to the adjacent stroma and benign areas are characterized by anergic and immunosuppressive phenotypes. In order for immunotherapies to produce robust anti‐tumor responses in prostate cancer, this exclusion barrier and immunosuppressive microenvironment must first be overcome. We have previously identified mesenchymal stem cells (MSCs) in primary and metastatic human prostate cancer tissue.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 28, 2018
- Source ID
- 10.1002/pros.23738
Entities
People
- Alan K Meeker
- Daniel L J Thorek
- John T Isaacs
- Timothy E Krueger
- W Nathaniel Brennen
Organizations
- Johns Hopkins University
- National Cancer Institute
- National Institutes of Health
- Prostate Cancer Foundation
- United States Department of Defense
- Washington University in St. Louis